Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA A1066V |
Therapy | MK2206 |
Indication/Tumor Type | urinary bladder cancer |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA A1066V | urinary bladder cancer | resistant | MK2206 | Preclinical - Cell culture | Actionable | In a preclinical study, a bladder cancer cell line harboring PIK3CA A1066V, along with KRAS and NRAS mutations, was resistant to MK2206 in culture (PMID: 25349966). | 25349966 |
PubMed Id | Reference Title | Details |
---|---|---|
(25349966) | Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. | Full reference... |